Loading...
Market
Story
Novo Nordisk Launches Wegovy in China at Fraction of US Price
Nov 18, 2024, 01:15 PM
Novo Nordisk has launched its popular obesity drug Wegovy in China, marking a significant milestone in the company's expansion in Asia. The drug will be sold at a fraction of the price it commands in the US. Initial prescriptions will roll out in Shanghai this week. This move positions Novo Nordisk to tap into China's rising demand for obesity treatments, unlocking a fast-growing market for its blockbuster franchise. China is the world's second-largest pharmaceuticals market.
View original story
Similar markets
< $500 million • 33%
$500 million - $1 billion • 33%
> $1 billion • 34%
< 1 million • 33%
1 - 2 million • 33%
> 2 million • 34%
Weight Loss • 25%
Reduced Heart Attack Risk • 25%
Improved Overall Health • 25%
Other • 25%
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
Above 50% • 25%
30%-50% • 25%
10%-30% • 25%
Below 10% • 25%
Yes • 50%
No • 50%
Anti-ageing • 25%
Weight loss • 25%
Heart disease reduction • 25%
Other • 25%
Below $1 billion • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
Above $2 billion • 25%